Products
Online Inquiry
Nintedanib esylate
Cat. No.:
0225LY-1246
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Nintedanib esylate is a triple angiokinase inhibitor that targets the PDGFR alpha/beta, FGFR 1/2/3, and VEGFR 1/2/3 pathways.
Synonym:
Intedanib; BIBF 1120 (esylate); Nintedanib ethanesulfonate salt; BIBF 1120; 656247-18-6; BIBF 1120 esylate; Nintedanib ethanesulfonate; OFEV; (3Z)-2,3-Dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-1H-indole-6-carboxylic acid methyl ester ethanesulfonate; (Z)-methyl 3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate ethanesulfonate
CAS No.:
656247-18-6
Compound CID:
135476717
Formula:
C31H33N5O4·C2H6O3S
Formula Weight:
649.76
Specification
Targets&IC50:
FGFR2: 37 nM; VEGFR1: 34 nM; VEGFR2: 13 nM; VEGFR3: 13 nM; PDGFRβ: 65 nM; PDGFRα: 59 nM; FGFR1: 69 nM; FGFR3: 108 nM
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Nintedanib esylate can be used in pulmonary fibrosis research to study the simultaneous blockade of VEGFR, PDGFR, and FGFR signaling.
Library Information
Target:
VEGFR; FGFR; PDGFR
Receptor:
FGFR1; FGFR2; FGFR3; PDGFRα; PDGFRβ; VEGFR1; VEGFR2; VEGFR3
Pathways:
Tyrosine kinase/adaptors; Angiogenesis
Plate Number:
AOCL-17
Plate Location:
a3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
101 mg/mL; 155.44 mM
ALogP:
2.9
HBA_Count:
4
HBD_Count:
2
Rotatable Bond:
9
